Travere Therapeutics, Inc. (NASDAQ: TVTX) announced on July 28, 2026, that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of U.S. financial markets. This filing sets the timeline for investors to assess the biopharmaceutical company’s performance during the period, with management scheduled to provide context through a live conference call and webcast at 4:30 p.m. ET.

The event aims to deliver transparency regarding Travere’s operational and financial health. Management will use the session to discuss the specific financial results and offer a general business update. Investors can access dial-in information and the live webcast via the Investor page on Travere’s website. Following the live broadcast, an archived recording of the call will remain available on the company’s website for 30 days.

Event Details

The following schedule applies to the earnings release and accompanying investor communications:

About Travere Therapeutics

Travere Therapeutics operates as a biopharmaceutical company focused on rare diseases. The organization states its mission is to help patients, families, and caregivers navigate life with rare conditions by identifying, developing, and delivering therapies. The company emphasizes collaboration with the rare disease community to understand diverse patient perspectives and forge new treatment paths.

Contact Information

For media inquiries, contact mediarelations@travere.com or call 888-969-7879. For investor relations inquiries, contact IR@travere.com or call 888-969-7879.

Kuehn Law, PLLC has launched an investigation into potential breaches of fiduciary duty by certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX). The probe centers on allegations of self-dealing, which the firm claims may have harmed shareholder interests. According to Kuehn Law, affected shareholders could be entitled to monetary damages and specific corporate governance reforms if misconduct is substantiated.

The investigation was announced on July 27, 2026, from New York. Kuehn Law is urging long-term holders of TVTX stock to contact the firm immediately to discuss their rights. The law firm emphasizes that there may be a limited window for shareholders to enforce their legal claims, making timely participation critical for those seeking recourse.

Sophia Anne Silayan is the designated point of contact for this investigation. Shareholders can reach her via email at sophiaanne@kuehn.law or by phone at (833) 672-0814. Kuehn Law states that initial consultations are free and carry no obligation for the investor. Furthermore, the firm covers all case costs, meaning clients do not pay out-of-pocket fees during the litigation process.

Key Contact Details

What This Means for Investors

The core allegation involves self-dealing by company leadership, suggesting that personal interests may have conflicted with their duties to the corporation and its shareholders. If proven, such breaches can lead to significant financial recovery for investors and mandatory changes to how the company is governed. Kuehn Law frames shareholder participation as essential for maintaining market integrity and fairness.

This announcement serves as an attorney advertisement. As noted in the release, prior results do not guarantee similar outcomes in future cases. Investors are advised to review the information carefully before engaging with the firm.